|
1
|
Gurney J, Young JL Jr, Roffers SD, Smith
MA and Bunin CR: Soft tissue sarcomas. Cancer Incidence and
Survival Among Children and Adolescents: United States SEER Program
1975–1995. Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young
JL and Bunin GR: SEER Program; Benthesda, MD: 1999
|
|
2
|
Flamant F, Rodary C, Rey A, Praquin MT,
Sommelet D, Quintana E, Theobald S, Brunat-Mentigny M, Otten J,
Voûte PA, et al: Treatment of non-metastatic rhabdomyosarcomas in
childhood and adolescence. Results of the second study of the
International Society of Paediatric Oncology: MMT84. Eur J Cancer.
34:1050–1062. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Crist W, Gehan EA, Ragab AH, Dickman PS,
Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R, et
al: The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol.
13:610–630. 1995.PubMed/NCBI
|
|
4
|
Donaldson SS: The value of adjuvant
chemotherapy in the management of sarcomas in children. Cancer.
55(Suppl): 2184–2197. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smith MA, Seibel NL, Altekruse SF, Ries
LA, Melbert DL, O'Leary M, Smith FO and Reaman GH: Outcomes for
children and adolescents with cancer: Challenges for the
twenty-first century. J Clin Oncol. 28:2625–2634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lager JJ, Lyden ER, Anderson JR, Pappo AS,
Meyer WH and Breitfeld PP; Soft Tissue Sarcoma Committee of the
Children's Oncology Group. Pooled analysis of phase II window
studies in children with contemporary high-risk metastatic
rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee
of the Children's Oncology Group. J Clin Oncol. 24:3415–3422. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carli M, Colombatti R, Oberlin O, Bisogno
G, Treuner J, Koscielniak E, Tridello G, Garaventa A, Pinkerton R
and Stevens M: European intergroup studies (MMT4-89 and MMT4-91) on
childhood metastatic rhabdomyosarcoma: Final results and analysis
of prognostic factors. J Clin Oncol. 22:4787–4794. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Breneman JC, Lyden E, Pappo AS, Link MP,
Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer
HM, et al: Prognostic factors and clinical outcomes in children and
adolescents with metastatic rhabdomyosarcoma - a report from the
Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 21:78–84. 2003.
View Article : Google Scholar
|
|
9
|
Walterhouse DO, Pappo AS, Meza JL,
Breneman JC, Hayes-Jordan AA, Parham DM, Cripe TP, Anderson JR,
Meyer WH and Hawkins DS: Shorter-duration therapy using
vincristine, dactinomycin, and lower-dose cyclophosphamide with or
without radiotherapy for patients with newly diagnosed low-risk
rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee
of the Children's Oncology Group. J Clin Oncol. 32:3547–3552. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weigel BJ, Lyden E, Anderson JR, Meyer WH,
Parham DM, Rodeberg DA, Michalski JM, Hawkins DS and Arndt CA:
Intensive multiagent therapy, including dose-compressed cycles of
ifosfamide/etoposide and vincristine/doxorubicin/cyclophosphamide,
irinotecan, and radiation, in patients with high-risk
rhabdomyosarcoma: A Report From the Children's Oncology Group. J
Clin Oncol. 34:117–122. 2016. View Article : Google Scholar
|
|
11
|
Altieri DC: Validating survivin as a
cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tanaka C, Uzawa K, Shibahara T, Yokoe H,
Noma H and Tanzawa H: Expression of an inhibitor of apoptosis,
survivin, in oral carcinogenesis. J Dent Res. 82:607–611. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reed JC: The Survivin saga goes in vivo. J
Clin Invest. 108:965–969. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ryan BM, Konecny GE, Kahlert S, Wang HJ,
Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, et al:
Survivin expression in breast cancer predicts clinical outcome and
is associated with HER2, VEGF, urokinase plasminogen activator and
PAI-1. Ann Oncol. 17:597–604. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rosato A, Pivetta M, Parenti A, Iaderosa
GA, Zoso A, Milan G, Mandruzzato S, Del Bianco P, Ruol A, Zaninotto
G, et al: Survivin in esophageal cancer: An accurate prognostic
marker for squamous cell carcinoma but not adenocarcinoma. Int J
Cancer. 119:1717–1722. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haberler C, Slavc I, Czech T, Gelpi E,
Heinzl H, Budka H, Urban C, Scarpatetti M, Ebetsberger-Dachs G,
Schindler C, et al: Histopathological prognostic factors in
medulloblastoma: High expression of survivin is related to
unfavourable outcome. Eur J Cancer. 42:2996–3003. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mori T, Doi R, Toyoda E, Koizumi M, Ito D,
Kami K, Kida A, Masui T, Kawaguchi Y and Fujimoto K: Regulation of
the resistance to TRAIL-induced apoptosis as a new strategy for
pancreatic cancer. Surgery. 138:71–77. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kawasaki H, Toyoda M, Shinohara H, Okuda
J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T and Tanigawa N:
Expression of survivin correlates with apoptosis, proliferation,
and angiogenesis during human colorectal tumorigenesis. Cancer.
91:2026–2032. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kato J, Kuwabara Y, Mitani M, Shinoda N,
Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J, et al:
Expression of survivin in esophageal cancer: Correlation with the
prognosis and response to chemotherapy. Int J Cancer. 95:92–95.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grossman D, Kim PJ, Schechner JS and
Altieri DC: Inhibition of melanoma tumor growth in vivo by survivin
targeting. Proc Natl Acad Sci USA. 98:635–640. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Olie RA, Simões-Wüst AP, Baumann B, Leech
SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel
antisense oligonucleotide targeting survivin expression induces
apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer
Res. 60:2805–2809. 2000.PubMed/NCBI
|
|
22
|
Yamamoto H, Ngan CY and Monden M: Cancer
cells survive with survivin. Cancer Sci. 99:1709–1714. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Uehara S, Oue T, Kawatsu M, Nara K and
Fukuzawa M: Increased expression of survivin in hepatoblastoma
after chemotherapy. Eur J Pediatr Surg. 23:400–404. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakahara T, Kita A, Yamanaka K, Mori M,
Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I,
Matsuhisa A, et al: YM155, a novel small-molecule survivin
suppressant, induces regression of established human
hormone-refractory prostate tumor xenografts. Cancer Res.
67:8014–8021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kita A, Nakahara T, Yamanaka K, Nakano K,
Nakata M, Mori M, Kaneko N, Koutoku H, Izumisawa N and Sasamata M:
Antitumor effects of YM155, a novel survivin suppressant, against
human aggressive non-Hodgkin lymphoma. Leuk Res. 35:787–792. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kumar B, Yadav A, Lang JC, Cipolla MJ,
Schmitt AC, Arradaza N, Teknos TN and Kumar P: YM155 reverses
cisplatin resistance in head and neck cancer by decreasing
cytoplasmic survivin levels. Mol Cancer Ther. 11:1988–1998. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakahara T, Yamanaka K, Hatakeyama S, Kita
A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T,
Koutoku H, et al: YM155, a novel survivin suppressant, enhances
taxane-induced apoptosis and tumor regression in a human Calu 6
lung cancer xenograft model. Anticancer Drugs. 22:454–462. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iwasa T, Okamoto I, Takezawa K, Yamanaka
K, Nakahara T, Kita A, Koutoku H, Sasamata M, Hatashita E, Yamada
Y, et al: Marked anti-tumour activity of the combination of YM155,
a novel survivin suppressant, and platinum-based drugs. Br J
Cancer. 103:36–42. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McAllister RM, Melnyk J, Finkelstein JZ,
Adams EC Jr and Gardner MB: Cultivation in vitro of cells derived
from a human rhabdomyosarcoma. Cancer. 24:520–526. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mir R, Stanzani E, Martinez-Soler F,
Villanueva A, Vidal A, Condom E, Ponce J, Gil J, Tortosa A and
Giménez-Bonafé P: YM155 sensitizes ovarian cancer cells to
cisplatin inducing apoptosis and tumor regression. Gynecol Oncol.
132:211–220. 2014. View Article : Google Scholar
|
|
31
|
Liang H, Zhang L, Xu R and Ju XL:
Silencing of survivin using YM155 induces apoptosis and
chemosensitization in neuroblastomas cells. Eur Rev Med Pharmacol
Sci. 17:2909–2915. 2013.PubMed/NCBI
|
|
32
|
Hawkins DS, Spunt SL and Skapek SX; COG
Soft Tissue Sarcoma Committee. Children's Oncology Group's 2013
blueprint for research: Soft tissue sarcomas. Pediatr Blood Cancer.
60:1001–1008. 2013. View Article : Google Scholar :
|
|
33
|
Zhang K, Li Y, Liu W, Gao X and Zhang K:
Silencing survivin expression inhibits the tumor growth of
non-small-cell lung cancer cells in vitro and in vivo. Mol Med Rep.
11:639–644. 2015.
|
|
34
|
Dai CH, Li J, Shi SB, Yu LC, Ge LP and
Chen P: Survivin and Smac gene expressions but not livin are
predictors of prognosis in non-small cell lung cancer patients
treated with adjuvant chemotherapy following surgery. Jpn J Clin
Oncol. 40:327–335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vallböhmer D, Drebber U, Schneider PM,
Baldus S, Bollschweiler E, Brabender J, Warnecke-Eberz U, Mönig S,
Hölscher AH and Metzger R: Survivin expression in gastric cancer:
Association with histomorphological response to neoadjuvant therapy
and prognosis. J Surg Oncol. 99:409–413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Augello C, Caruso L, Maggioni M, Donadon
M, Montorsi M, Santambrogio R, Torzilli G, Vaira V, Pellegrini C,
Roncalli M, et al: Inhibitors of apoptosis proteins (IAPs)
expression and their prognostic significance in hepatocellular
carcinoma. BMC Cancer. 9:1252009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Islam A, Kageyama H, Takada N, Kawamoto T,
Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y,
et al: High expression of Survivin, mapped to 17q25, is
significantly associated with poor prognostic factors and promotes
cell survival in human neuroblastoma. Oncogene. 19:617–623. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wachtel M and Schäfer BW: Targets for
cancer therapy in childhood sarcomas. Cancer Treat Rev. 36:318–327.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fulda S: Apoptosis pathways and their
therapeutic exploitation in pancreatic cancer. J Cell Mol Med.
13:1221–1227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Simon-Keller K, Paschen A, Hombach AA,
Ströbel P, Coindre JM, Eichmüller SB, Vincent A, Gattenlöhner S,
Hoppe F, Leuschner I, et al: Survivin blockade sensitizes
rhabdomyosarcoma cells for lysis by fetal acetylcholine
receptor-redirected T cells. Am J Pathol. 182:2121–2131. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Caldas H, Holloway MP, Hall BM, Qualman SJ
and Altura RA: Survivin-directed RNA interference cocktail is a
potent suppressor of tumour growth in vivo. J Med Genet.
43:119–128. 2006. View Article : Google Scholar
|
|
42
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chakravarti A, Zhai GG, Zhang M, Malhotra
R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q and Loeffler J:
Survivin enhances radiation resistance in primary human
glioblastoma cells via caspase-independent mechanisms. Oncogene.
23:7494–7506. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Iwasa T, Okamoto I, Suzuki M, Nakahara T,
Yamanaka K, Hatashita E, Yamada Y, Fukuoka M, Ono K and Nakagawa K:
Radiosensitizing effect of YM155, a novel small-molecule survivin
suppressant, in non-small cell lung cancer cell lines. Clin Cancer
Res. 14:6496–6504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tolcher AW, Mita A, Lewis LD, Garrett CR,
Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P,
et al: Phase I and pharmacokinetic study of YM155, a small-molecule
inhibitor of survivin. J Clin Oncol. 26:5198–5203. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Giaccone G, Zatloukal P, Roubec J, Floor
K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A and
Shamsili S: Multicenter phase II trial of YM155, a small-molecule
suppressor of survivin, in patients with advanced, refractory,
non-small-cell lung cancer. J Clin Oncol. 27:4481–4486. 2009.
View Article : Google Scholar : PubMed/NCBI
|
